Abstract:This study examines the pivotal role of the PD‐1/PD‐L1 immune checkpoint interaction in tumor immunotherapy. Due to the absence of mature small molecule inhibitors in the market, exploring novel PD‐L1 small molecule inhibitors is imperative. Utilizing asymmetric biphenyl compounds developed by BMS Corporation, we assembled 39 small molecule compounds with analogous biphenyl scaffolds from the literature. By employing QSAR methods, these compounds were randomly divided into training and test sets, facilitating the successful construction of CoMFA and CoMSIA models, and thereby laying the groundwork for further research. Extracting insights from the spatial fields depicted in the three‐dimensional contour maps, including the electrostatic field, hydrophobic field, and hydrogen bond donor field, the most active molecule, 37, was selected from the training set. Its specific positions were modified, and functional groups were added to enhance its activity. Based on this, a series of structurally novel and potentially active small molecule compounds (37 a–37 e) were designed. Comprehensive studies were conducted on one of these compounds, 37 c, including molecular docking, molecular dynamics simulations, ADME predictions, and other operations, confirming its closer interaction with the amino acid residues of the PD‐L1 dimer in comparison to 37. This study offers new insights and options for the development of PD‐L1‐based small molecule inhibitors through the application of computational techniques and rational drug design principles. Blocking the interaction between programmed cell death‐1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1) is a crucial immunotherapeutic strategy for cancer. Currently, all inhibitors available on the market that target PD‐1/PD‐L1 are monoclonal antibodies, with no small molecule drugs yet accessible. This study focused on PD‐L1 and conducted three‐dimensional quantitative structure‐activity relationship (3D‐QSAR) research on 39 PD‐L1 inhibitors using Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). The CoMFA (q2=0.593, r2=0.991) and CoMSIA (q2=0.542, r2=0.971) models were successfully established. Based on these models, a series of structurally novel and potentially active PD‐L1 inhibitors (37 a–37 e) were designed. Among these compounds, 37 c exhibited superior performance, with CoMFA predicting a pIC50 value of 9.204 and CoMSIA predicting a pIC50 value of 8.597. Further molecular docking and molecular dynamics simulations revealed that compound 37 c establishes hydrophobic interactions with BTyr56 and BVal68 of PD‐L1, engages in hydrogen bonds with AAsp122, ALys124, and BTyr123, and forms electrostatic interactions with ALys124 and AMet115. The design of this biphenyl series of inhibitors offers additional options for the development of small molecule inhibitors targeting PD‐L1, with 37 c expected to be a promising inhibitor of PD‐L1.

Progress on Biphenyl Derivatives As PD-1/PD-L1 Inhibitors

Design, Synthesis and Biological Evaluation of Biphenyl-1,2,3-Triazole Hybrid Analogues as PD-1/PD-L1 Inhibitors

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Design of Biphenyl‐Type Programmed Cell Death‐Ligand 1 Inhibitors Using 3D‐QSAR, Molecular Docking, and Molecular Dynamics Simulation

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges

Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors

Design, Synthesis, And Evaluation Of O-(Biphenyl-3-Ylmethoxy)Nitrophenyl Derivatives As Pd-1/Pd-L1 Inhibitors With Potent Anticancer Efficacy In Vivo

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction

Design, Synthesis, and Evaluation of <i>o</i>-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy <i>In Vivo</i>

Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Discovery of Phenyl-Linked Symmetric Small Molecules As Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy

Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

Advancing Cancer Immunotherapy through Engineering New PD-L1 Degraders: A Comprehensive Study from Small Molecules to PD-L1-Specific Peptide-Drug Conjugates

Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy

Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction

Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors